A carregar...
(177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites
The present study aimed at exploring the patient and imaging characteristics of primary neuroendocrine tumors (NETs) of rare sites who presented with metastatic and/or advanced inoperable stages and therefore was considered for peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE. A re...
Na minha lista:
| Publicado no: | World J Nucl Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Medknow Publications & Media Pvt Ltd
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5460307/ https://ncbi.nlm.nih.gov/pubmed/28670182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1450-1147.207283 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|